Lipella Pharmaceuticals Inc. (LIPO) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Pittsburgh, PA, 미국. 현재 CEO는 Jonathan Kaufman.
LIPO 을(를) 보유 IPO 날짜 2022-12-19, 5 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $101.66K.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
